EUCTR2018-003441-42-IT进行中（未招募）1 期
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction (HFpEF) - DETERMINE-preserved
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Provision of signed informed consent prior to any study specific procedures
- •2.Male or female, aged = 40 years
- •3.Documented diagnosis of symptomatic HF (NYHA functional class II-IV), which has been present for at least 8 weeks, optimally treated with pharmacotherapy and/or device therapy with at least intermittent need for diuretic treatment.
- •4.LVEF >40% and evidence of structural heart disease documented by the most recent echocardiogram, or cardiac magnetic resonance imaging within the last 12 months prior to enrolment.
- •5.NT-proBNP = 250 pg/mL at Visit 1 for patients without ongoing atrial fibrillation/flutter. If a trial fibrillation/flutter is present at Visit 1, NTproBNP must be =500 pg/mL.
- •6.Patients should receive background standard of care as described below: All patients will be treated according to locally recognised guidelines on standard of care treatment for patients with HFpEF. Therapy should have been individually optimised and stable for = 4 weeks (this does not apply to diuretics) and include (unless contraindicated or not tolerated) treatment of co morbidities (including high blood pressure, ischaemic heart disease, atrial fibrillation/flutter).
- •7.6MWD =100 metres and = 425 metres at both the Enrolment and Randomisation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 250
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 250
排除标准
- •1.Presence of any condition that precludes exercise testing.
- •2.Participation in a structured exercise training programme in the 1 month prior to screening or planned to start during the trial.
- •3.Receiving therapy with an SGLT2 inhibitor within 4 weeks prior to randomisation or previous intolerance to an SGLT2 inhibitor.
- •4.Type 1 diabetes mellitus.
- •5.eGFR <25 mL/min/1.73 m2 (CKD-EPI formula) at visit 1, unstable or rapidly progressing renal disease at time of randomisation.
- •6.Systolic BP <95 mmHg on 2 consecutive measurements at 5-minute intervals, at Visit 1 or at Visit 2a/b.
- •7.Systolic BP=160 mmHg if not on treatment with =3 blood pressure lowering medications or =180 mmHg irrespective of treatments, on 2 consecutive measurements at 5-minute intervals, at Visit 1 (Enrolment) or at Visit 2a/b
- •8.Current acute decompensated HF or hospitalisation due to decompensated HF <4 weeks prior to enrolment.
- •9.Myocardial infarction, unstable angina, coronary revascularization ablation of atrial fibrillation/flutter, valve repair/replacement, implantation of a cardiac resynchronization therapy device within 12 weeks prior to enrolment.
- •10.Planned coronary revascularization, ablation of atrial fibrillation/flutter and/or valve repair/replacement.
- •11.Stroke or transient ischemic attack within 12 weeks prior to enrolment.
- •12.Probable alternative or concomitant diagnoses which could account for the patient's HF symptoms and signs.
- •13.Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD.
- •14.Previous cardiac transplantation, or complex congenital heart disease. Planned cardiac resynchronisation therapy. Prior implantation of a ventricular assistance device or similar device, or implantation expected after randomization.
- •15.HF due to any of the following: known infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia, or uncorrected primary valvular disease.
- •16.A life expectancy of <2 years due to any non-cardiovascular condition, based on Investigator's clinical judgement.
- •17.Active malignancy requiring treatment (with the exception of basal cell or squamous cell carcinomas of the skin).
- •18.Acute or chronic liver disease with severe impairment of liver function (eg, ascites, oesophageal varices, coagulopathy).
- •19.Women of child-bearing potential not willing to use a medically accepted method of contraception considered reliable in the judgment of the Investigator OR who have a positive urine pregnancy test at randomisation OR who are breast-feeding.
- •20.Involvement in the planning and/or conduct of the study (applies to both AstraZeneca personnel and/or personnel at the study site).
- •21.Previous randomisation in the present study.
- •22.Participation in another clinical study with an IP or device during the last month prior to enrolment.
- •23.Inability of the patient, in the opinion of the Investigator, to understand and/or comply with studwith study medications, procedures and/or follow-up (especially completing ePRO assessments) OR any conditions that, in the opinion of the Investigator, may render the patient unable to complete the study. Therefore, patients who are unable to read (eg, are blind or illiterate) should be excluded from participating in this trial.
研究者
相似试验
进行中（未招募）
1 期
DETERMINE-preserved – Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with preserved ejection fractioHeart Failure Patients with Preserved Ejection Fraction (HFpEF)MedDRA version: 20.1Level: LLTClassification code 10076396Term: Heart failure with preserved ejection fractionSystem Organ Class: 100000004849EUCTR2018-003441-42-BGAstraZeneca AB500
进行中（未招募）
1 期
DETERMINE-reduced – Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fractioEUCTR2018-003442-16-DKAstraZeneca AB300
进行中（未招募）
1 期
DETERMINE-reduced – Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fractioHeart Failure Patients with Reduced Ejection Fraction (HFrEF)MedDRA version: 20.0Level: LLTClassification code 10078289Term: Heart failure with reduced ejection fractionSystem Organ Class: 100000004849EUCTR2018-003442-16-SEAstraZeneca AB300
进行中（未招募）
1 期
DETERMINE-preserved – Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with preserved ejection fractioEUCTR2018-003441-42-DKAstraZeneca AB500
进行中（未招募）
1 期
DETERMINE-preserved – Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with preserved ejection fractioHeart Failure Patients with Preserved Ejection Fraction (HFpEF)MedDRA version: 20.1Level: LLTClassification code 10076396Term: Heart failure with preserved ejection fractionSystem Organ Class: 100000004849EUCTR2018-003441-42-SEAstraZeneca AB500